Rigel Pharmaceuticals | RIGL - Ebit


Rigel Pharmaceuticals reported $447K in EBIT for its fiscal quarter ending in June of 2024.





Ebit Change Date
Agenus USD 15.05M 656K Mar/2026
Amgen USD 4.61B 777M Jun/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -154.34M 13.08M Jun/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
BioMarin Pharmaceutical USD 105.6M 24.04M Jun/2026
Bristol-Myers Squibb USD 299M 3.26B Jun/2026
Celldex Therapeutics USD -80.62M 3.81M Jun/2026
Daiichi Sankyo JPY 85.1B 4.44B Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Halozyme Therapeutics USD -63.72M 1.95M Jun/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Intrexon USD -26.3M 2.91M Jun/2024
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Ligand Pharmaceuticals USD 56.62M 3.7M Jun/2026
MacroGenics USD -31.88M 19.79M Mar/2026
Neurocrine Biosciences USD 219.9M 5.3M Jun/2026
Pfizer USD -180M 5.16B Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Rigel Pharmaceuticals USD 447K 1.52M Jun/2024
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Veracyte USD 23.96M 4.88M Jun/2026